(Press-News.org) Despite the success of recent approved therapeutics to treat advanced melanoma, metastatic cancer cells inevitably evolve resistance to drugs. In the journal Cell Reports, a team of researchers based at The Wistar Institute, report on the mechanics by which melanoma can evolve resistance to a powerful combination of drugs—BRAF and MEK inhibitors.
They found that resistant melanomas acquired a mutation in the MEK2 gene and multiple copies of the mutant BRAF oncogene, simultaneously decreasing the sensitivity to both drug targets. Their findings also uncovered a new potential target for melanoma therapy, a protein called S6K. Additionally, early studies in a laboratory model for melanoma show that a triple combination of drug inhibitors halted the growth of resistant tumors.
"Melanoma tumors are particularly adept at rewiring themselves so that anticancer drugs lose their effectiveness, and we must continue to outthink the disease in order to block off all points at which it can evade therapy," said Jessie Villanueva, Ph.D., assistant professor in Wistar's NCI-designated Cancer Center and member of The Wistar Institute Melanoma Research Center. "There are currently therapeutics available that can block the pathway that leads to S6K, but we are also interested in developing inhibitors to S6K itself."
Melanoma is the deadliest, most aggressive form of skin cancer. While surgical treatment of early-stage melanoma leads to 90 percent cure rates, advanced melanoma is notoriously resistant to chemotherapy and has a tendency to metastasize, or spread, throughout the body. According to the World Health Organization, cases of the disease continue to rise internationally, which has helped spur research into therapies such as BRAF and MEK inhibitors.
BRAF inhibitors were developed in response to discoveries that a specific mutation in the BRAF gene was responsible for nearly 50 percent of melanoma cases. The BRAF protein is part of the MAP kinase pathway, a chain of enzymatic reactions—including the enzyme MEK—that is commonly over-activated in cancers.
"Combining BRAF and MEK inhibitors was conceived as a one-two punch against the MAP kinase pathway," Villanueva said, "and while it is considered successful in the clinic, some tumors do not respond and others develop resistance, underscoring the need for new therapeutic strategies."
As cancer clinicians began to see patients develop resistance to BRAF and MEK inhibitors, the Wistar team began to explore the mechanisms by which tumors develop resistance. They found that melanoma cells used different tactics for each enzyme. Mutations in MEK2, for example, would render anti-MEK therapies ineffective. To defeat BRAF inhibitors, surviving melanoma cells exhibited numerous copies of the mutant BRAF gene, enough to overpower anti-BRAF drugs.
"There were simply too many copies of BRAF to block, it became a numbers game and the mutation was winning," Villanueva said. "Increasing the dosage of BRAF inhibitors could be one solution, but that cannot be done in patients without causing serious toxic effects."
A possible answer, they reasoned, was in the PI3K/mTOR pathway, a network of signaling enzymes often active within melanoma cells. However, they could find no sign that any of the "usual suspects"—points along the pathway commonly known to be involved in cancers—had any evident part in BRAF/MEK resistance. It was not until they examined farther "downstream" that they found persistent activation of S6K, an enzyme that appears to be at the point where P13K/mTOR and MAP kinase pathways merge.
So the researchers tried combinations of inhibitors against BRAF, MEK and PI3K/mTOR (as there are currently no effective S6K inhibitors) in a mouse model of melanoma. "With a triple combination of drugs, the tumors slow down and just stop growing," Villanueva explained.
Although a cocktail of two drugs (a combination of BRAF and PI3K/mTOR inhibitors, for example) might work, they postulated that using three drugs could be more potent and counter intuitively less toxic at the same time. "We followed these mice with melanoma for three weeks, tumors remain stable, and mice did not show any evident signs of toxicity, " Villanueva said
"For patients, it is not a simple matter of introducing triple combination therapies into use," Villanueva said, " but now we have a mechanism and a rational approach to develop both new drugs and more effective combinations aimed at solving drug resistance in melanoma. Our findings might also offer important lessons for other forms of metastatic cancer."
INFORMATION:
Wistar collaborators include Clemens Krepler, M.D., Patricia Reyes-Uribe, Minu Samanta, Hsin-Yi Chen, Ph.D., Rolf K. Swoboda, Ph.D., Adina Vultur, Ph.D., Mizuho Fukunaba-Kalabis, M.D., Ph.D., Thomas Y. Chen,, Qin Liu, M.D., Ph.D., Ronen Marmorstein, Ph.D., David C. Schultz, Ph.D., David W. Speicher, Ph.D., and Meenhard Herlyn, D.V.M., D.Sc. Co-authors also include Jeffrey R. Infante, M.D. from the Sarah Cannon Research Institute; Bin Li, Ph.D., Bradley Wubbenhorst, Giorgios Karakousis, M.D., Wei Xu, M.D., Ravi K. Amaravadi, M.D., Xiaowei Xu, M.D., Ph.D., Lynn M. Schuchter, M.D., Melissa Wilson, M.D., Ph.D., and Katherine Nathanson, M.D., from the University of Pennsylvania, and Douglas J. DeMarini, Ph.D., Anne-Marie Martin, Ph.D., and Tona M. Gilmer, Ph.D., from GlaxoSmithKline.
These studies were funded by grants from the National Cancer Institute (PO1 CA114046, CA093372, P30 CA010815), the CURE Program of the Pennsylvania Department of Health, The V Foundation for Cancer Research, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and research funds from GlaxoSmithKline.
END
It is difficult to underestimate the importance of telomerase, an enzyme that is the hallmark of both aging and the uncontrolled cell division associated with cancer. In an effort to understand and control telomerase activity, researchers at The Wistar Institute have discovered a protein "motif," named TFLY, which is crucial to the function of telomerase. Altering this motif disrupts telomerase function, they found, a fact that they believe will help them in their efforts to identify inhibitors of telomerase with potential cancer therapeutic properties.
Their findings ...
If the development of our nervous system is disturbed, we risk developing serious neurological diseases, impairing our sensory systems, movement control or cognitive functions. This is true for all organisms with a well-developed nervous system, from man to worm. New research from BRIC, University of Copenhagen reveals how a tiny molecule called mir-79 regulates neural development in roundworms. The molecule is required for correct migration of specific nerve cells during development and malfunction causes defects in the nervous system of the worm. The research has just ...
Thursday, September 19, 2013, Cleveland: Overweight patients with type 2 diabetes continue to experience the benefits of bariatric surgery up to nine years after the procedure, according to new research from Cleveland Clinic's Bariatric & Metabolic Institute, published online today in the journal, Annals of Surgery.
Prior research has shown that bariatric surgery effectively treats diabetes and reduces cardiovascular risk factors, but few studies have reported the long-term metabolic effects of bariatric surgery. This trial shows that obese patients with type 2 diabetes ...
COLUMBUS, Ohio -- Some overweight older adults don't need to lose weight to extend their lives, but they could risk an earlier death if they pack on more pounds.
In fact, the nationwide study found that people who were slightly overweight in their 50s but kept their weight relatively stable were the most likely to survive over the next 16 years.
They had better survival rates than even normal-weight individuals whose weight increased slightly, but stayed within the normal range.
On the other hand, those who started out as very obese in their 50s and whose weight continued ...
Berkeley — Calcium can do much more than strengthen bones. The mineral is a critical nutrient for healthy tree growth, and new research shows that adding it to the soil helps reverse the decades-long decline of forests ailing from the effects of acid rain.
The paper, published today (Thursday, Sept. 19), in the journal Environmental Science and Technology (EST) Letters, and led by John Battles, professor of forest ecology at the University of California, Berkeley, also presents strong evidence that acid rain impairs forest health.
The paper reports on 15 years of ...
Scientists have successfully analysed the genetic make-up of the offspring of pregnant coelacanth females for the first time. They found that the likelihood that the offspring is fathered by one single individual is very high – unlike with many other fish species. Dr Kathrin Lampert from the Ruhr-Universität Bochum and Prof Dr Manfred Schartl from the University of Würzburg, together with their colleagues, report about their findings in the journal "Nature Communications".
Analysis of the microsatellite DNA
The pregnant coelacanth females studied by the researchers ...
The breakthrough concerns a gene called OPA1, which when mutated is responsible for dominant optic atrophy, a hereditary visual disease characterized by a progressive and symmetrical loss vision that becomes apparent early in life.
In an in-depth study of OPA1, groups led by Dr. Luca Scorrano, professor of Biochemistry at the University of Padua and researcher of the Dulbecco Telethon Institute, and Dr. José Antonio Enríquez, coordinator of the Tissue Homeostasis and Repair Program at the CNIC, found that this gene has the capacity to act as a "helper" in cellular metabolism, ...
A piece of research submitted by the Artificial Intelligence and Approximate Reasoning Group (GIARA) of the NUP/UPNA-Public University of Navarre received an award from the European Association of Fuzzy Logic and Soft Computing (EUSFLAT) during its biennial meeting (EUSFLAT 2013) held in Milan last week. The researchers have developed a method that improves the delimitation of tumours in medical images. As they explained, "when the doctor decides where tumour tissue should be separated from healthy tissue, our algorithm ensures that he/she is never going choose the worst ...
The entorhinal cortex is a link between the brain's memory centre, the hippocampus, and the other areas of the brain. It is, however, more than an interface that only transfers nervous impulses. The entorhinal cortex also has an independent role in learning and thinking processes. This is particularly applicable for spatial navigation. "We know precious little about how this happens," says Prof. Dietmar Schmitz, a researcher at the Cluster of Excellence NeuroCure at the Charité – Universitätsmedizin Berlin and Site Speaker for the DZNE in Berlin. "This is why we are investigating ...
WASHINGTON -- Eight-year-old twin boys, camping in a backyard tent, received penetrating blast injuries when a bolt of lightning struck a transformer near their tent, sending them to the emergency department for treatment. The extremely rare case study was published online yesterday in Annals of Emergency Medicine. ("'Thunderstruck' -- Penetrating Thoracic Injury from Lightning Strike")
"One of the boys had a missile trajectory through the lung -- very much like injuries caused by improvised explosive devices (IEDs) -- which we could have missed because on the outside ...
